NuPathe quiet period ends September 14

NuPathe, a specialty pharma seeking approval for Zelrix, a patch for migraine treatment, will see its quiet period end on Tuesday, September 14. On August 5, the company raised $50 million by offering 5 million shares at $10, below the range of $14-$16. Leerink Swann and Lazard Capital Markets acted as lead managers on the deal.